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Postmortem studies in Parkinson’s disease
Andreas Hartmann, MD
No animal model to date perfectly replicates Parkinson’s
disease (PD) etiopathogenesis, and the anatomical orga-
nization of the nigrostriatal system differs considerably
between species. Human postmortem material therefore
remains the gold standard for both formulating
hypotheses for subsequent testing in in vitro and in vivo
PD models and verifying hypotheses derived from exper-
imental PD models with regard to their validity in the
human disease. This article focuses on recent and rele-
vant fields in which human postmortem work has gen-
erated significant impact in our understanding of PD.
These fields include Lewy body formation, regional vul-
nerability of dopaminergic neurons, oxidative/nitrative
cellular stress, inflammation, apoptosis, infectious and
environmental agents, and nondopaminergic lesions. 
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he history of human postmortem studies in
Parkinson’s disease (PD) begins at the end of the 1950s
with two seminal papers:Carlsson’s original suggestion
that dopamine (DA) may be a transmitter in the central
nervous system (CNS) and be involved in the control of
motor function,and thus in the parkinsonian syndrome
1;
and the article by Ehringer and Hornykiewicz,
2 which
proved the significant reduction in DA concentration in
the neostriatum of patients suffering from sporadic PD.
In 1973, these initial observations were followed by
demonstration of a correlation between DA cell loss in
the substantia nigra pars compacta (SNpc,Figure 1) and
striatal DA concentrations in PD.
3 Interestingly,this study
suggested that the classical parkinsonian symptom triad
of PD appears when striatal DA concentrations are low-
ered by approximately 80%;however,this decline corre-
sponds to only 50% of SNpc DA neuron loss,suggesting
that a subset of nigral DA neurons may be morphologi-
cally intact,but functionally impaired.This concept is sup-
ported by the finding that 15% of melanized neurons in
the human SNpc no longer express tyrosine hydroxylase
(TH; the rate-limiting enzyme in DA synthesis), but
remain morphologically intact.
4This concept of the suf-
fering,ie,metabolically compromised,neuron is impor-
tant in pathophysiological and therapeutic terms,since it
suggests that a subpopulation of nigral DA neurons are
amenable to restorative therapies.
After a general outline on the potential and limitations
of human postmortem studies in PD,I will explore major
questions regarding etiology,pathogenesis,and treatment
of PD with reference to human postmortem studies.
The role of human postmortem 
studies in PD research
There has been considerable debate over the importance
of human postmortem studies in PD research.This con-
troversy is based on the many limitations of postmortem
research.Human postmortem studies in PD suffer from
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tissue confounds of aging,end-stage disease,and chronic
treatments.Moreover,human postmortem studies can-
not answer the question of whether the changes observed
are a cause or a consequence of neuronal death in PD.
On the other hand, no animal model to date perfectly
replicates PD etiopathogenesis,and the anatomical orga-
nization of the nigrostriatal system differs considerably
between humans and lower species.Thus,human post-
mortem material remains the gold standard for (i) for-
mulating hypotheses for subsequent testing in in vitro
and in vivo PD models (cell culture,yeast,Drosophila,
rodent,and primates models of the disease,based on tox-
ins and/or genetic manipulations); and (ii) verifying
hypotheses derived from experimental PD models with
regard to their validity in the human disease.This review
will emphasize the interaction of findings from post-
mortem and experimental PD studies.
Genes and PD
The etiology of sporadic PD remains unknown.It is gen-
erally believed that sporadic PD is the result of complex
interactions between genetic susceptibility and environ-
mental factors.In both cases,postmortem studies serve to
confirm rather than to generate new hypotheses,with a
few notable exceptions.
Genetics is a rapidly growing field in PD research.Three
major mutations have been identified to date in affected
kindreds: α-synuclein or Park1
5; parkin or Park2
6; and 
DJ-1 or Park7.
7A fourth mutated gene product,UCHL1
(Park5),is associated with gene expression;it may not be
able to provoke a parkinsonian syndrome alone,
8 but may
be a susceptibility gene.
9Autopsy specimens from families
with these mutations remain rare,but have nevertheless
yielded results that have expanded our understanding of
sporadic PD,such as the data on α-synuclein.
Three different point mutations in α-synuclein, A53T,
A30P,and E46K,have been associated with PD in sepa-
rate families with dominantly transmitted PD.
5,10,11These
are gain-of-function mutations.There is also evidence
that α-synuclein promoter variants contribute to the life-
time risk of sporadic PD.
12-14 In general, alleles that
increase α-synuclein expression are associated with an
increased risk for PD.Recent work has shown that trip-
lication of the α-synuclein gene is sufficient to cause PD
and,in human postmortem brain,is accompanied by dou-
bling of α-synuclein protein expression.
15,16 Similarly,
postmortem studies in sporadic PD show that α-synu-
clein mRNA is upregulated in the SNpc of affected indi-
viduals.
17
The link between α-synuclein and sporadic PD is found
in Lewy bodies (LBs),the pathological hallmark of PD,
since α-synuclein has been shown to be the primary con-
stituent of LBs.
18-22 LBs are eosinophilic fibrillar cyto-
plasmic inclusions in DA neurons that can be detected in
both the SNpc and the cortex of PD patients (Figure 2).
LBs are located in the cell body,axons,and dendrites of
neurons,and are composed of neurofilaments 7 to 25 nm
in diameter; these neurofilaments are believed to be
inappropriately phosphorylated, proteolytically trun-
cated, and ubiquitinated.
23 LBs have been reported to
include a wide range of proteins (including ubiquitin,
parkin,and tau),heat shock proteins (HSPs),torsin A,
neurofilaments,oxidized/nitrated proteins,proteasomal
elements, and others.
22,24-31 Interestingly, many proteins
that interact with α-synuclein and parkin have also been
Selected abbreviations and acronyms
DA dopamine
DAT dopamine transporter
DLB dementia with Lewy bodies
LB Lewy body
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
PD Parkinson’s disease
SNpc substantia nigra pars compacta
VMAT2 vesicular monoamine transporter 2
Figure 1. Axial cut of human mesencephalon. The substantia nigra pars
compacta (SNpc) can be identified by tyrosine hydroxylase (TH)
immunostaining reflecting the presence of dopaminergic (DA)
neurons. Cell loss in the parkinsonian SNpc can be appreciated
macroscopically by decrease of staining density compared to
the control case. RN, red nucleus; CP, cerebral peduncle.
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identified as components of LBs, for instance, parkin-
associated endothelin-like receptor (Pael-R; a trans-
membrane polypeptide),
32 synphilin-1,
33 and p38 (a struc-
tural component of the mammalian aminoacyl-tRNA
synthetase complex).
34 LBs ectopically express the cell
cycle protein cyclin B;this may be related to cyclin B’s
interaction with α-synuclein, which predisposes nigral
LB-bearing DA neurons to undergo apoptosis.
35Another
protein colocalized with α-synuclein in LBs is tissue
transglutaminase (tTGase),which induces cross-linking
of α-synuclein in vitro.
36 tTGase inhibition could there-
fore be a novel therapeutic target in PD,provided that
LB formation is indeed a cytotoxic event.
Parkin is widely distributed protein in DA and non-DA
neurons in normal human brain and in sporadic PD.It is
mostly located in large cytoplasmic vesicles and in the
endoplasmic reticulum (ER).
37 The initial postmortem
studies from five parkin-positive cases initially failed to
find LBs—an observation used to argue that parkin is
required for LB formation.
38,39 However,this conclusion
was challenged when Farrer et al
40 showed the presence of
LBs in one parkin-positive autopsy case.These studies
highlight the importance of postmortem study data and
their conclusions.They guide our clinical formulations,and
thus our experimental and therapeutic approaches.
Finally,studies with DJ-1 are in very early stages.Its dis-
tribution has been analyzed in postmortem brain of con-
trol and PD subjects in two recent studies.DJ-1 does not
colocalize with LBs,but with tau inclusions;it is mainly
expressed by astrocytes;and it appears to be sensitive to
oxidative stress.
41,42At present,a functional interpretation
of these data is lacking.
The role of LBs in DA cell death
There remains much debate over whether LBs are neu-
roprotective,constitute an age-related epiphenomenon,
or are cytotoxic; postmortem end points may supply
some answers.Recently,Conway et al
43,44 suggested that
accelerated formation of nonfibrillar α-synuclein
oligomers is the critical process in PD pathogenesis,ie,
LB formation is neuroprotective by sequestering toxic
protein species.Once this issue is resolved,drug therapy
can be aimed at promoting the healthy process. Two
observations from pathological examination of human
brain contribute to this dialogue:
• SNpc DA neurons containing LB appear to be “health-
ier”than neighboring neurons,
45 whereas the nigral DA
neurons undergoing apoptotic-like cell death do not
contain somal LBs.Tompkins and Hill
45 suggested that
the majority of SNpc neurons die before or without
forming LBs and that SNpc neurons that survive the
initial pathological insult suffer damage that leads to
LB formation.
• It is not uncommon to observe “incidental” LBs at
autopsy of aged asymptomatic individuals.An alterna-
tive explanation for this finding is that these individu-
als have not lived long enough to develop a parkinson-
ian phenotype.Also,if LBs were protective,one might
speculate that controls should have more LBs than PD
patients,which is clearly not the case.
Alternatively,LBs may occur as an epiphenomenon of
the primary pathology and have little or no effect on neu-
ronal viability. In contrast to the observations by
Tompkins and Hill,
45 Gibb and Lees
46 reported that SNpc
neurons with and without somal LBs generally appear to
be similarly affected by the disease process.Moreover,
cell size and nucleolar size do not differ between LB-pos-
itive and LB-negative SNpc neurons.
47 Also, dendritic
morphological abnormalities found in parkinsonian
SNpc are similar in LB- and non–LB-containing neu-
rons.
48 Finally,neurofilament mRNA levels also show a
Figure 2. A Lewy body (LB). The LB is shown as a dense eosinophilic
inclusion bordered by neuromelanin, the auto-oxidation prod-
uct of dopamine (DA), which allows identification of DA neu-
rons in the human substantia nigra pars compacta (SNpc).Basic research
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similar level of reduction for both LB- and non–LB-con-
taining neurons.
49
We favor the hypothesis that the presence of LBs is an
indicator of neuronal distress,although it is impossible to
deduce from postmortem work whether LBs are,as such,
neurotoxic.The percentage of LB-containing neurons that
are positive for caspase-3 and Bax,two proapoptotic pro-
teins,is significantly higher than the percentage of Bax–
and caspase-3–positive DA neurons not containing LBs,
50,51
which indicates that LB-containing DA neurons are more
predisposed to undergo apoptosis. Furthermore, aggre-
gated proteins bind HSPs in LBs,and thus prevent their
potentially protective chaperone action.
52 Entrapment of
vital cellular organelles in LBs has been described and
may compromise cellular viability.
53Also,LBs may inhibit
axonal transport,probably resulting in a “dying back”phe-
nomenon from the synapse to the cell body.
52 Clinical neu-
ropathological studies in patients with dementia with LBs
(DLB) report a correlation between numbers of cortical
LBs and the degree of cognitive impairment.
54,55 Finally,we
have recently conducted a human postmortem study,
where the genetic fingerprints of mesencephalic DA neu-
rons containing LBs versus mesencephalic DA neurons
not containing LBs were compared in five PD patients.
Total RNA from single neurons of both neuronal sub-
populations was obtained by immuno-laser capture
microdissection (LCM). Subsequently, RNA arbitrarily
primed polymer chain reaction (RAP-PCR) was
employed to generate expression profiles from the
extracted RNA.Seven expressed sequence tags (ESTs) of
interest were selected for further quantitative expression
analysis by real-time quantitative reverse transcription
PCR (rtq RT-PCR).DA neurons bearing LBs,according
to their genetic profile,appeared sicker than their LB-neg-
ative counterparts, which were preferentially endowed
with prosurvival genes.This suggests that inhibition of LB
formation indeed represents a therapeutic strategy in PD
(Lu and Hartmann,unpublished results).
Figure 3. Summary of midbrain subdivisions illustrated at three representative transverse levels. CGS, central gray substance; M, medial group; Mv,
medioventral group (M and Mv constitute the ventral tegmental area [VTA]); A8, dopaminergic group A8; SNpd, substantia nigra pars dor-
salis; SNpl, substantia nigra pars lateralis; N, nigrosome; RN, red nucleus; DBC, decussation of the brachium conjunctivum; CP, cerebral
peduncle; III, exiting third cranial nerve fibers. 
Reproduced with permission from reference 58: Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of
dopamine-containing neurons in Parkinson's disease. Brain. 1999;122(Pt 8):1437-1448. Copyright © 1999. Oxford University Press.
Rostral Intermediate Caudal
CGS
M
Mv
CP
CP
III
Pons
DBC
N5
N3
N4
N1
N1
N2
N2
RN RN
A8
SNpd
SNpl
Matrix
Matrix
MatrixPostmortem studies in Parkinson’s disease - Hartmann Dialogues in Clinical Neuroscience - Vol 6 . No.3 . 2004
285
A differential vulnerability of mesencephalic
DA neurons to degeneration
There is evidence that the loss of DA neurons in PD is
heterogeneous.DA neurons in the SNpc are affected,as
are those in other mesencephalic structures,eg,the ven-
tral tegmental area (VTA) and the central gray substance
(CGS).These DA neuronal populations display a differ-
ential vulnerability to cell death in PD.SNpc DA neurons
are most affected,with a cell loss averaging 80% to 90%
in PD patients,whereas cell loss in the VTA is interme-
diate at 40% to 50%.Finally,only 2% to 3% of DA neu-
rons degenerate in the CGS in PD.
56 For the PD mid-
brain,the correlation is simple and direct:the greater the
number of pigmented neurons normally present in the
DA cell groups,the larger the loss of neurons in the cell
groups in the diseased brains.Moreover,within each cell
group,nonpigmented neurons are spared relative to the
total population of TH-positive neurons and relative to
the population of pigmented neurons.
4 There is also a
regional selective vulnerability of DA neurons within the
SNpc to cell death in PD.
57-59 On the basis of calbindin
D28K (CD28K) immunohistochemistry,the SNpc can be
divided into a calbindin-rich region (matrix) and five cal-
bindin-poor pockets (nigrosomes 1-5) (Figure 3).T h e
depletion of DA neurons begins in nigrosome 1,and then
spreads to other nigrosomes and matrix along the rostral,
medial,and dorsal axes.Depletion is maximum (98%) in
nigrosome 1,located in the caudal and mediolateral part
of the SNpc.Progressively,less cell loss is detectable in
more medial and more rostral nigrosomes.A parallel,but
lesser,caudorostral gradient of cell loss is observed for
DA neurons included in the matrix.Because the nigro-
some/matrix analysis refers to compartmental subdivi-
sions within the SNpc, the most obvious conclusion
would be that compartmental locality in SNpc itself is a
key to differential vulnerability.DA neurons in different
compartments may have different expression patterns of
genes implicated in PD pathogenesis.The DA neurons
relatively spared from the disease process may be
endowed with a range of protective mechanisms,which
has sparked research aiming to identify these protective
or deleterious mechanisms.
Whether CD28K determines neuronal vulnerability itself
is controversial, and both positive and negative results
have been reported.CD28K-positive neurons have been
shown to be relatively resistant to degeneration in PD
59
and in certain animal models of PD.
60-62There is also a sig-
nificant decrease in CD28K protein and mRNA in the SN,
but not in the cerebellum and neocortex of PD patients
compared with controls.
63 However,on the basis of the via-
bility assessment of midbrain DA neurons in a 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesion para-
digm using CD28K-deficient mice, CD28K-containing
neurons are not spared by the pathological process,sug-
gesting that endogenous CD28K is not required for pro-
tection of these neurons.
64Thus,CD28K may be a marker
of resistance of DA neurons to the degenerative process
in PD,but not the causative agent itself.
Perturbation of regulated balance 
between DAT and VMAT2
It has been proposed that the process underlying PD is
the selective degeneration of DA nerve terminals in the
striatum expressing dopamine transporter (DAT) and
vesicular monoamine transporter 2 (VMAT2).
65-68 DAT
and VMAT2 are essential for normal DA neurotrans-
mission: DAT terminates the actions of DA by rapidly
removing it from the synapse;and VMAT2 loads cyto-
plasmic DA into synaptic vesicles for storage and subse-
quent release.Cytosolic DA can quickly form reactive
oxygen species,and so DA that has been synthesized or
transported into the neuron from the extracellular space
is rendered harmless by rapid storage in small synaptic
vesicles.Hence,DAT activity increases cytoplasmic DA
concentrations,whereas VMAT2 activity decreases them.
Detailed neuroanatomical analyses of brain from control
and PD cases have shown that the regions with the high-
est DAT/VMAT2 ratio—the caudate and the putamen—
are the most sensitive to damage in PD and MPTP-
induced parkinsonism.
67,69,70A recent study showed that
α-synuclein negatively modulates human DAT activity,
71
whereas an earlier study found opposite results.
72 The
A53T mutation of expression of α-synuclein also reduced
levels of VMAT2.Taken together,the defective seques-
tration of DA mediated by the interplay of DAT,
VMAT2,and α-synuclein may be a key event in the DA
cell death in sporadic PD.
73
To extend the one gene/one protein approach to the
search for the differences in mesencephalic regional vul-
nerability to cell death,we compared the genetic finger-
prints of mesencephalic DA neurons that are particularly
prone to degenerate during PD (DA neurons in nigro-
some 1 within the SNpc) and mesencephalic DA neurons
that are particularly resistant to the disease course (DAneurons in the CGS) in five control subjects.We found
that SNpc DA neurons do not per se reveal many dis-
tinctive deleterious genes;rather,it appeared as if CGS
DA neurons were just embodied with more cellular
defenses against degeneration,suggesting that the trans-
fer of these factors might endow SNpc DA neurons with
the same resistance against neuronal death in PD (Lu
and Hartmann,unpublished results).
Defects of the ubiquitin-proteasome 
system in PD
A growing body of evidence suggests that proteolytic
stress underlies both familial and sporadic PD.Interest
in the role of the proteasome in the pathophysiology of
PD has been triggered by observation of parkin,an E3
ubiquitin ligase,which tags (potentially neurotoxic) pro-
teins for degradation by the proteasome. Proteasomes
are multicatalytic proteases found in the cytoplasm,ER,
perinuclear region,and the nucleus of eukaryotic cell.
74
The accumulation of oxidized proteins in SNpc suggests
that protein clearance is inadequate in this brain region.
75
Compared with the brains of age-matched controls,in the
brains of subjects with sporadic PD, there is a marked
loss of α- but not β-subunits of 20S proteasome core
within nigral DA neurons.
76 Levels of PA28 (a multisub-
unit proteasome activator) are very low in the SNpc of
both control and PD subjects.
77These findings point to
a primary defect in proteasome-mediated proteolysis of
nigral DA neurons in sporadic PD.Dysfunction at any
point on the proteasome pathway may result in nigral
DA neuronal degeneration,accounting for the particular
vulnerability of nigral DA neurons to neurodegenera-
tion.Although low proteasomal activity has been linked
to LB formation by some,
78 it has been refuted by oth-
ers.
79The production of abnormal proteins that resist and
inhibit proteolysis (α-synuclein mutations), defects in
protein ubiquitination (parkin mutations),reduced de-
ubiquitination (UCH-L1/Park5 mutations),and protea-
somal dysfunction (sporadic PD) have all been impli-
cated in the etiopathogenesis of PD (Figure 4).
Oxidative stress
One of the first and most relevant hypotheses for PD
pathogenesis relates to increased oxidative/nitrative
stress in mesencephalic DA neurons. In PD, DA can
auto-oxidize into toxic dopamine-quinone species,super-
oxide radicals,and hydrogen peroxide.DA auto-oxidizes
into neuromelanin,the phenotypic marker of midbrain
DA neurons in humans.Accordingly,the neuromelanin
content and distribution in the parkinsonian mesen-
cephalon has been linked to the vulnerability of DA neu-
rons to undergo cell death.
80 Oxidative/nitrative stress
may result in protein oxidation/nitration
81,82;decreased
neuronal glutathione and glutathione peroxidase content,
which prevents inactivation of hydrogen peroxide and
enhances formation of toxic hydroxyl radicals
83-85;basal
lipid peroxidation,which results in membrane damage
86;
DNA and RNA oxidation
75,87;and formation of LBs.
88
A potential signaling pathway between oxidative stress
and subsequent cell death has been explored by Hunot et
al.
89They showed that nuclear translocation of the nuclear
factor–κB (NF-κB),which is triggered by oxidative stress
and precedes the engagement of an apoptotic program,is
increased 70-fold in nigral DA neurons from PD subjects
compared with control subjects.Oxidative stress has also
been implicated in altered iron,ferritin,and trace metal
contents of nigral DA neurons and may increase the sus-
ceptibility of these neurons to cell death.
90-92 Prior to caus-
ing cell death, increased iron in the brain has been sug-
gested to trigger LB formation and initiation of
inflammatory responses.
93 Interestingly,the detection of
redox-active iron in situ showed a strong labeling of LBs
in the SNpc of PD patients,whereas cortical LBs remained
Basic research
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Figure 4. Possible relationship and interplay between proteolytic stress
and other prominent observations in Parkinson’s disease.
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cortical and brain-stem LBs.
94 Similarly, Giasson et al
95
reported that nitrated α-synuclein is present in the major
filamentous building blocks of LBs,underlining the impor-
tance of oxidative/nitrative stress in PD.
Inflammation
The degeneration of DA neurons is associated with a
strong glial reaction,which is generally considered to be a
nonspecific consequence of neuronal degeneration.
However,there is increasing evidence that inflammation
is an active phenomenon in PD,continuously triggering
DA cell death in this neurodegenerative disorder. The 
glial reaction in the SN of PD patients is a well-known
neuropathological characteristic of the disease. In their
seminal study, McGeer and McGeer 
96 reported a large
number of reactive human leukocyte antigen-DR (HLA-
DR)–positive microglial cells in the SN of PD patients.
Such a glial reaction has also been described in the
affected brain regions in other neurological disorders,such
as Alzheimer’s disease and brain infarct,
97 as well as in ani-
mal models of PD.
98These data suggest that glial activation
is not specific to PD and that it most likely represents a
common phenomenon in neurodegenerative disorders.
However,recent evidence supports the notion that a sub-
population of activated glial cells may be deleterious in
PD,particularly for highly dysfunctional neurons that are
metabolically compromised. Strong support for this
hypothesis came from a study of young drug addicts who
developed a parkinsonian syndrome after MPTP intoxi-
cation.
99 In a recent study, the same authors reported a
postmortem neuropathological study of three subjects
with MPTP-induced parkinsonism.
100 Interestingly,gliosis
and clustering of microglial cells around DA neurons were
detected,despite survival times ranging from 3 to 16 years.
These findings not only indicate an ongoing nerve cell loss
after a time-limited insult,but also suggest that activated
microglial cells may perpetuate neuronal degeneration.
One may thus speculate that after a primary insult of envi-
ronmental and/or genetic origin, the glial reaction may
perpetuate the degeneration of DA neurons.
The mechanism by which microglial cells can amplify
injury to nigral DA neurons is not yet known.However,
the factors involved in this deleterious effect are very likely
cytokines, including tumor necrosis factor α (TNF-α),
interleukin 1β (Il-1β), and interferon γ (IFN-γ). Ac-
cordingly, several studies have reported a marked
increase of cytokine levels in the brain and cerebrospinal
fluid (CSF) of PD patients.
101 In addition,a higher den-
sity of glial cells expressing TNF-α,Il-1β,and IFN-γ was
observed in the SN of PD patients compared with age-
matched control subjects.
102,103 Some of these cells were
close to blood vessels and degenerating DA neurons,sug-
gesting their involvement in the pathophysiology of PD.
Two mechanisms,which are not mutually exclusive,may
explain the deleterious role of cytokines in the parkin-
sonian SNpc:
• Proinflammatory cytokines induce the production of
nitric oxide in glial cells.
104
•TNF-α receptors directly activate DA neurons of the
human SN.
102
The question of whether inflammation plays a prominent
role in PD pathogenesis cannot be resolved by post-
mortem studies alone,and experimental PD models have
much contributed to strengthening this hypothesis,mak-
ing inflammation a prime candidate for neuroprotective
studies in PD patients.
98 Importantly,recent primate stud-
ies have replicated chronic glial activation in the SNpc
following a time-limited MPTP insult
105-107 and may thus
represent a valuable model to study the long-term con-
sequences of this process.
Apoptosis
There has been much interest in whether DA neurons in
PD die by apoptosis,necrosis,or some other form of cell
death.This is because apoptosis is amenable to pharma-
cological inhibition and may thus be a therapeutic target
in PD. The initial human postmortem studies showed
conflicting results,
51 either because of methodological
problems, especially the unreliability of 3’ DNA end
labeling as a marker of apoptotic nuclear degradation,
108
or because the apoptotic changes observed might in fact
represent a perimortem effect rather than the primary
disease process.
109
Thus,the next step was to look at the cellular transduc-
tion pathways mediating apoptosis in PD brains.In this
respect, the signaling pathways downstream of the
inflammatory release of proinflammatory cytokines,eg,
coupled to the TNF type 1 receptor (TNFR1),are of par-
ticular interest, given previous work on inflammation
triggering cell death in PD.TNF-α induces trimerization
of TNFR1 on binding,which leads to the autoproteolyt-
ical activation of caspase-8 via the adaptor molecule
TNFR1-associating protein with a death domain and
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Caspase-8 may in turn either cleave effector caspases,
such as caspase-3, directly or amplify the death signal
through the mitochondrial release of cytochrome-c into
the cytosol.
110 Indeed,in a human postmortem study,we
showed a significant decrease in the percentage of
FADD immunoreactive DA neurons in the SNpc of PD
patients compared with control subjects.
111 Furthermore,
this decrease correlated with the known selective vul-
nerability of nigral DA neurons in PD, suggesting that
this pathway contributes to the susceptibility of DA neu-
rons to TNF-mediated apoptosis in PD.One step down-
stream in this proapoptotic signaling cascade, the pro-
portion of melanized neurons displaying caspase-8
activation in PD was also higher in PD than in control
subjects.
112 Similar results were obtained for caspase-3,
where we found (i) a positive correlation between the
degree of neuronal loss in DA cell groups affected in the
mesencephalon of PD patients and the percentage of cas-
pase-3–positive neurons in these cell groups in control
subjects;(ii) a significant decrease in caspase-3–positive
pigmented neurons in the SNpc of PD patients compared
with control subjects;and (iii) a significantly higher per-
centage of active caspase-3–positive neurons among DA
neurons in PD compared with control subjects.
50Taken
together, these studies suggest that the melanized DA
neurons expressing the TNFR1 transduction pathway are
particularly prone to degeneration in PD if this pathway
is activated during the course of the disease.
As regards mitochondrial proteins controlling apoptosis
in PD,we have shown a similar distribution of nigral DA
neurons immunoreactive for Bax,a proapoptotic mito-
chondrial protein, in PD compared with control sub-
jects.
113 However,by assessing staining intensity,Tatton
114
reported increased immunoreactivity for Bax and cas-
pase-3 in nigral DA neurons of PD compared with con-
trol subjects.We also studied the mRNA expression of
Bcl-xL,a major anti-apoptotic mitochondrial protein in
the SNpc of PD patients and controls.We found a signif-
icant upregulation of Bcl-xL mRNA expression in nigral
DA neurons from PD patients, as assessed by in situ
hybridization,which was accompanied by a redistribu-
tion of the protein to the mitochondrial outer membrane,
as assessed by electron microscopy.
115This process sug-
gests a compensatory upregulation of Bcl-xL in the nigral
DA neurons surviving the pathological process in PD.
Finally,an experimental link between sublethal activa-
tion of apoptotic pathways and LB formation has been
suggested by Hashimoto et al,
116 who showed that release
of cytochrome-c from mitochondria into the cytosol may
also function as a stimulator for α-synuclein aggregation.
Environmental toxins
The seminal study by Langston et al
99 on MPTP as the
causative agent for a PD-like syndrome has triggered
numerous studies on the role of environmental toxins in
the pathophysiology of PD.Since MPTP inhibits complex
I of the mitochondrial respiratory chain,a defect in this
protein has been investigated in cases of sporadic PD.In
1990,Schapira et al
117 showed that complex I activity is
indeed decreased in the SNpc of patients suffering from
sporadic PD.Environmental toxins,particularly herbi-
cides and pesticides that inhibit complex I activity,such
as rotenone,paraquat,and maneb,have since been stud-
ied as potential causative or at least risk factors in PD
models and in epidemiological studies.
118 However,only
limited human postmortem data have been gathered so
far.Fleming et al
119 screened postmortem brain samples
from PD patients and control cases for 16 organochlo-
ride pesticides.They found a positive association of PD
and pesticide concentrations for only one pesticide,dield-
rin,a lipid-soluble mitochondrial poison.These results
were replicated by another group in separate studies with
regard to increased dieldrin concentration in PD brain.
120-122
However,the mode of action of this pesticide strongly
supports current concepts of oxidative stress and mito-
chondrial energy impairment as an important factor in
PD pathogenesis.Interestingly,the pesticides dieldrin,
paraquat, and rotenone, which are all complex I
inhibitors,have been shown to induce an acceleration of
α-synuclein fibril formation in vitro,and thus likely Lewy
body formation.
123
Infection
The idea of a putative role of infectious agents in the eti-
ology of PD can be traced back to 1918, when posten-
cephalitic parkinsonism due to influenza A infection was
widespread in Europe.Many decades later,observations
of sporadic PD suggest that LBs harbor viral and bacte-
rial signatures.
124 A very recent study has convincingly
shown that Nocardia asteroides 16S rRNA is present in
LBs from PD patients and points to a role in bacterial
infection in protein aggregation.
125These findings,how-
ever,need to be confirmed in larger samples.The same
Basic research
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monkeys infected with N.asteroides developed intracel-
lular inclusion bodies (immunoreactive for α-synuclein
and ubiquitin); the infected monkey also expressed
rRNA for N. asteroides. Other viral and bacterial
pathogens need to be studied in human postmortem
brain tissue of PD patients using more recent virological
and bacterial detection methods.
126
Non-DA cell loss in PD
The concept of a specific neurotransmitter deficiency
associated with a specific neurological syndrome poten-
tially amenable to replacement therapy,as exemplified
by the initial studies of Carlsson,
1 Ehringer and
Hornykiewicz,
2 and Bernheimer,
3 has somehow obscured
the fact that PD is not a disease restricted to the nigro-
striatal system and involving solely DA as neurotrans-
mitter.In fact,postmortem studies have shown that much
of the peripheral and central nervous systems (stellate
ganglia, cardiac, and enteric plexus, nucleus basalis of
Meynert, amygdala, limbic nuclei of the thalamus,
parahippocampal and cingulate gyri,insula,and isocor-
tex) and transmitter systems (serotonin,noradrenaline,
and acetylcholine) are affected in PD,albeit at varying
degrees.
56 This explains the comorbidity of PD with
depression,
127 dementia,
128 autonomic dysfunction,
129 and
sleep disorders.
130The common link between degenera-
tion in these structures and/or transmitter systems may
be the presence of LBs,which stresses their importance
in PD pathogenesis.
The studies of Braak’s group are of special interest here.
In large series of individuals suffering from PD or in the
preliminary stages,the distribution of LBs appears to fol-
low a specific temporal (subdivided into stages 1 to 6)
and anatomical distribution:lesions initially occur in the
dorsal motor nucleus of the glossopharyngeal and vagal
nerves and anterior olfactory nucleus.Thereafter, less
vulnerable nuclear grays and cortical areas gradually
become affected.The disease process in the brain stem
then pursues an ascending course.Cortical involvement
ensues,beginning with the anteromedial temporal meso-
cortex.Next,the neocortex is affected,commencing with
higher order sensory association and prefrontal areas.
First-order sensory association/premotor areas and pri-
mary sensory/motor fields are affected last.
131,132
Braak et al
133 have speculated that PD might originate
outside the CNS, caused by an as yet unidentified
pathogen capable of passing the mucosal barrier of the
gastrointestinal tract and,via postganglionic enteric neu-
rons,entering the CNS along unmyelinated preganglionic
fibers generated from the visceromotor projection cells
of the vagus nerve. By way of retrograde axonal and
transneuronal transport, such a causative pathogen (a
toxin and/or infectious agent?) could reach selectively
vulnerable subcortical nuclei and,unimpeded,gain access
to the cerebral cortex.At present,the experimental argu-
ments supporting this intriguing hypothesis are sparse,
especially because the relationship between neuronal
degeneration and LB formation is still unclear.
134
However, considering current evidence, it is plausible
that the presence of LBs indicates a disease process and
reflects neuronal suffering.
Conclusion and perspectives
Human postmortem studies remain the mainstay of our
understanding of PD.Despite considerable advances in
modeling PD,none of the experimental models available
today reflects all the major characteristics of the disease in
humans. Human postmortem studies and experimental
PD paradigms should be closely associated to study ques-
tions related to etiology and/or pathogenesis.Future major
research topics will include the role of protein aggregation,
LB formation,and proteasomal dysfunction in pathogen-
esis,and their relationship to DA metabolism,accounting
for the selectivity of lesions in PD.The role of environ-
mental toxins and infectious agents in the etiology of PD
and in relation to susceptibility genes should also be an
area of vigorous research. The microglial reaction and
chronic inflammation will also be major therapeutic tar-
gets to slow PD progession.Interestingly,an inverse cor-
relation between the intake of nonsteroidal anti-inflam-
matory drugs (NSAIDs) and the risk for PD has recently
been claimed by an extensive epidemiological study.
135 In
this regard, it would undoubtedly be of great value to
study the brains of individuals with a long-standing history
of NSAID intake to seek the presence (or absence) of PD-
like pathology.With respect to these questions,we should
emphasize the need to collect donor brains in specialized
brains banks to supply the field of human postmortem PD
research.
136 Specifically,brain bank characterization of PD
brain samples and other neurodegenerative diseases in the
postgenomic era must include the genotype and pheno-
type of the affected individuals as well as thorough clini-
cal data. ❏
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Estudios postmortem en la enfermedad de
Parkinson
A la fecha, ningún modelo animal ha podido repro-
ducir perfectamente la etiopatogenia de la enfer-
medad de Parkinson (EP). Además, la organización
anatómica del sistema nigroestriatal difiere consi-
derablemente entre las especies. Es por esto que los
estudios postmortem en humanos continúan siendo
el gold standard tanto para la formulación de hipó-
tesis que serán probadas posteriormente en mode-
los de EP in vivo e in vitro, como también para la
verificación de hipótesis que deriven de modelos
experimentales de EP respecto a su validez para la
enfermedad en el hombre. Este artículo se centra
en campos recientes y relevantes en los que el tra-
bajo postmortem en humanos ha generado un
impacto significativo para nuestra comprensión de
la EP. Estos campos incluyen la formación de cuer-
pos de Lewy, la vulnerabilidad regional de las neu-
ronas dopaminérgicas, el estrés celular de la oxida-
ción y de la nitratación, la inflamación, la apoptosis,
los agentes infecciosos y ambientales, y las lesiones
no dopaminérgicas. 
Études post mortem dans la maladie de
Parkinson
Aucun modèle animal à ce jour ne reproduit fidè-
lement l’étiopathogenèse de la maladie de
Parkinson (MP). Aussi, l’organisation anatomique
du système nigrostrié varie considérablement d’une
espèce à l’autre. C’est pourquoi les études post
mortem chez l’homme restent la meilleure appro-
che soit pour formuler des hypothèses qui seront
ensuite testées dans des modèles in vitro et in vivo
de la MP, soit pour vérifier des hypothèses dérivées
de modèles expérimentaux de la MP, quant à leur
validité en pathologie humaine. Dans cet article,
l’accent sera mis sur des domaines de recherche
récents et pertinents, tels que la formation de corps
de Lewy, la vulnérabilité régionale des neurones
dopaminergiques, le stress cellulaire lié à l’oxyda-
tion et la nitration, l’inflammation, l’apoptose, les
agents infectieux et environnementaux ainsi que
les lésions non dopaminergiques, où les études post
mortem chez l’homme ont contribué de manière
significative à notre compréhension de la MP.
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